References
- Tiedemann R E, Gonzalez-Paz N, Kyle R A, Santana-Davila R, Price-Troska T, Van Wier S A, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044–1052
- Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12: 1977–1982
- Gertz M A. Managing plasma cell leukemia. Leuk Lymphoma 2007; 48: 5–6
- Cha C H, Park C J, Huh J R, Chi H S, Suh C W, Kang Y K. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol 2007; 118: 178–182
- Finnegan D P, Kettle P, Drake M, Matthews C, Alexander H D, Popat R, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006; 47: 1670–1673
- Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leuk Res 2008; 32: 1153–1156
- Durie B G, Harousseau J L, Miguel J S, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473
- Costello R, Sainty D, Bouabdallah R, Fermand J P, Delmer A, Divine M, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res 2001; 25: 103–107
- Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008; 26: 480–492
- Kim S J, Kim J, Cho Y, Seo B K, Kim B S. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol 2007; 37: 382–384
- Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109: 2285–2290
- Bertheau P, Turpin E, Rickman D S, Espie M, de Reynies A, Feugeas J P, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin–cyclophosphamide regimen. PLOS Med 2007; 4: e90
- Oakervee H E, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762